

April 17, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company's Directors

SymBio Pharmaceuticals Limited (“the Company”) today announced the following details regarding the issuance of stock acquisition rights to the Company's Directors (the 68th Series SymBio Stock Options) pursuant to the resolution approved at the Board of Directors' meeting held on March 24, 2026. The issuance of the stock acquisition rights does not constitute an issuance on favorable terms under applicable regulations.

1. Number of stock acquisition rights

8,943 units (in total for 5 directors)

Allocation Details:

- Representative Director: 1 individual
- External Directors (excluding Audit Committee members): 4 individuals
- Total: 5 individuals

2. Class and number of shares to be issued upon exercise of the stock acquisition rights

The Company's common stock: 223,575 shares

3. Amount to be paid for the stock acquisition rights and calculation method

(1) Amount to be paid per unit: : 2,400 yen

(2) Amount to be paid per share: : 96 yen

Payment Method: Each recipient shall pay for the stock acquisition rights by offsetting the acquisition payment against compensation (including salary, bonus, and other remuneration) owed by the Company to such recipient, in lieu of payment in cash.

(Note)

For further information regarding the stock acquisition rights, please refer to the Company's press release dated March 24, 2026 titled “Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors.”

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125